Liquidia (NASDAQ:LQDA) Director Sells $8,948,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total transaction of $8,948,000.00. Following the completion of the sale, the director directly owned 501,477 shares in the company, valued at $44,872,161.96. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Liquidia Stock Down 0.0%

Shares of Liquidia stock opened at $86.80 on Friday. Liquidia Corporation has a 1 year low of $16.82 and a 1 year high of $91.10. The firm has a market cap of $7.72 billion, a price-to-earnings ratio of 620.04 and a beta of 0.55. The company has a 50-day moving average of $73.31 and a 200 day moving average of $51.72. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s revenue was up 4187.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Needham & Company LLC raised their price target on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $79.00 price target (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.18.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently added to or reduced their stakes in the company. TCG Crossover Management LLC purchased a new stake in Liquidia during the 3rd quarter valued at $38,887,000. MPM Bioimpact LLC increased its holdings in shares of Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after purchasing an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in shares of Liquidia in the third quarter worth $12,571,000. Bank of America Corp DE raised its stake in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Liquidia by 428.3% during the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after purchasing an additional 341,009 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).